DOCSLIB.ORG

PERIOLIMEL N4E, Emulsion for Infusion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PERIOLIMEL N4E, Emulsion for Infusion Olimel/Periolimel - FR/H/0419/001-006/MR Page 1 of 32 Proposed common SmPC consolidated March 2013 PERIOLIMEL N4E, emulsion for infusion OLIMEL N5E, emulsion for infusion OLIMEL N7E, emulsion for infusion OLIMEL N9E, emulsion for infusion OLIMEL N7, emulsion for infusion OLIMEL N9, emulsion for infusion SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) English master Proposed version – March 2013 Annotated version In order to facilitate the review, this document consists in a combined SmPC for all strenghts. This annotated version includes all revised wording clearly identified using track-changes mode with the following annotations: - Grey-shaded titles the strength in which alternative text elements refer. Grey-shaded text is used to highlight text which will not be included in each separated SPC. - Information to be filled in is presented using the following bracket {text}. - Text to be selected or deleted as appropriate is presented using the following bracket <text>. Confidential Document Olimel/Periolimel - FR/H/0419/001-006/MR Page 2 of 32 Proposed common SmPC consolidated March 2013 1. NAME OF THE MEDICINAL PRODUCT <PERIOLIMEL N4E, emulsion for infusion OLIMEL N5E, emulsion for infusion OLIMEL N7E, emulsion for infusion OLIMEL N9E, emulsion for infusion OLIMEL N7, emulsion for infusion OLIMEL N9, emulsion for infusion> 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <PERIOLIMEL / OLIMEL> is presented in the form of a 3-compartment bag. For PERIOLIMEL N4E, OLIMEL N5E, OLIMEL N7E and OLIMEL N9E: <Each bag contains a glucose solution with calcium, a lipid emulsion and an amino acid solution with other electrolytes.> For OLIMEL N7 and OLIMEL N9: <Each bag contains a glucose solution, a lipid emulsion and an amino acid solution.> For PERIOLIMEL N4E: Contents per bag 1000 ml 1500 ml 2000 ml 2500 ml 18.75 % Glucose solution 400 ml 600 ml 800 ml 1000 ml (corresponding to 18.75 g/100 ml) 6.3 % Amino acid solution 400 ml 600 ml 800 ml 1000 ml (corresponding to 6.3 g/100 ml) 15 % Lipid emulsion 200 ml 300 ml 400 ml 500 ml (corresponding to 15 g/100 ml) For OLIMEL N5E : Contents per bag 1500 ml 2000 ml 2500 ml 28.75 % Glucose solution 600 ml 800 ml 1000 ml (corresponding to 28.75 g/100 ml) 8.2 % Amino acid solution 600 ml 800 ml 1000 ml (corresponding to 8.2 g/100 ml) 20 % Lipid emulsion 300 ml 400 ml 500 ml (corresponding to 20 g/100 ml) For OLIMEL N7E: Contents per bag 1000 ml 1500 ml 2000 ml 35% Glucose solution 400 ml 600 ml 800 ml (corresponding to 35 g/100 ml) 11.1% Amino acid solution 400 ml 600 ml 800 ml (corresponding to 11.1 g/100 ml) 20% Lipid emulsion 200 ml 300 ml 400 ml (corresponding to 20 g/100 ml) Confidential Document Olimel/Periolimel - FR/H/0419/001-006/MR Page 3 of 32 Proposed common SmPC consolidated March 2013 For OLIMEL N9E: Contents per bag 1000 ml 1500 ml 2000 ml 27.5 % Glucose solution 400 ml 600 ml 800 ml (corresponding to 27.5 g/100 ml) 14.2 % Amino acid solution 400 ml 600 ml 800 ml (corresponding to 14.2 g/100 ml) 20 % Lipid emulsion 200 ml 300 ml 400 ml (corresponding to 20 g/100 ml) For OLIMEL N7: Contents per bag 1000 ml 1500 ml 2000 ml 35 % Glucose solution 400 ml 600 ml 800 ml (corresponding to 35 g/100 ml) 11.1 % Amino acid solution 400 ml 600 ml 800 ml (corresponding to 11.1 g/100 ml) 20 % Lipid emulsion 200 ml 300 ml 400 ml (corresponding to 20 g/100 ml) For OLIMEL N9: Contents per bag 1000 ml 1500 ml 2000 ml 27.5 % Glucose solution 400 ml 600 ml 800 ml (corresponding to 27.5 g/100 ml) 14.2 % Amino acid solution 400 ml 600 ml 800 ml (corresponding to 14.2 g/100 ml) 20 % Lipid emulsion 200 ml 300 ml 400 ml (corresponding to 20 g/100 ml) Confidential Document Olimel/Periolimel - FR/H/0419/001-006/MR Page 4 of 32 Proposed common SmPC consolidated March 2013 Composition of the reconstituted emulsion after mixing the contents of the 3 compartments: For PERIOLIMEL N4E: Active substances 1000 ml 1500 ml 2000 ml 2500 ml Refined olive oil + refined soybean oila 30.00 g 45.00 g 60.00 g 75.00 g Alanine 3.66 g 5.50 g 7.33 g 9.16 g Arginine 2.48 g 3.72 g 4.96 g 6.20 g Aspartic acid 0.73 g 1.10 g 1.46 g 1.83 g Glutamic acid 1.26 g 1.90 g 2.53 g 3.16 g Glycine 1.76 g 2.63 g 3.51 g 4.39 g Histidine 1.51 g 2.26 g 3.02 g 3.77 g Isoleucine 1.26 g 1.90 g 2.53 g 3.16 g Leucine 1.76 g 2.63 g 3.51 g 4.39 g Lysine 1.99 g 2.99 g 3.98 g 4.98 g (equivalent to lysine acetate) (2.81 g) (4.21 g) (5.62 g) (7.02 g) Methionine 1.26 g 1.90 g 2.53 g 3.16 g Phenylalanine 1.76 g 2.63 g 3.51 g 4.39 g Proline 1.51 g 2.26 g 3.02 g 3.77 g Serine 1.00 g 1.50 g 2.00 g 2.50 g Threonine 1.26 g 1.90 g 2.53 g 3.16 g Tryptophan 0.42 g 0.64 g 0.85 g 1.06 g Tyrosine 0.06 g 0.10 g 0.13 g 0.16 g Valine 1.62 g 2.43 g 3.24 g 4.05 g Sodium acetate, trihydrate 1.16 g 1.73 g 2.31 g 2.89 g Sodium glycerophosphate, hydrated 1.91 g 2.87 g 3.82 g 4.78 g Potassium chloride 1.19 g 1.79 g 2.38 g 2.98 g Magnesium chloride, hexahydrate 0.45 g 0.67 g 0.90 g 1.12 g Calcium chloride, dihydrate 0.30 g 0.44 g 0.59 g 0.74 g Glucose anhydrous 75.00 g 112.50 g 150.00 g 187.50 g (equivalent to glucose monohydrate) (82.50 g) (123.75 g) (165.00 g) (206.25 g) a: Mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to a ratio essential fatty acids / total fatty acids of 20%. Confidential Document Olimel/Periolimel - FR/H/0419/001-006/MR Page 5 of 32 Proposed common SmPC consolidated March 2013 For OLIMEL N5E: Active substances 1500 ml 2000 ml 2500 ml Refined olive oil+ refined soybean oila 60.00 g 80.00 g 100.00 g Alanine 7.14 g 9.52 g 11.90 g Arginine 4.84 g 6.45 g 8.06 g Aspartic acid 1.43 g 1.90 g 2.38 g Glutamic acid 2.47 g 3.29 g 4.11 g Glycine 3.42 g 4.56 g 5.70 g Histidine 2.95 g 3.93 g 4.91 g Isoleucine 2.47 g 3.29 g 4.11 g Leucine 3.42 g 4.56 g 5.70 g Lysine 3.88 g 5.18 g 6.47 g (equivalent to lysine acetate) (5.48 g) (7.30 g) (9.13 g) Methionine 2.47 g 3.29 g 4.11 g Phenylalanine 3.42 g 4.56 g 5.70 g Proline 2.95 g 3.93 g 4.91 g Serine 1.95 g 2.60 g 3.25 g Threonine 2.47 g 3.29 g 4.11 g Tryptophan 0.82 g 1.10 g 1.37 g Tyrosine 0.13 g 0.17 g 0.21 g Valine 3.16 g 4.21 g 5.26 g Sodium acetate, trihydrate 2.24 g 2.99 g 3.74 g Sodium glycerophosphate, hydrated 5.51 g 7.34 g 9.18 g Potassium chloride 3.35 g 4.47 g 5.59 g Magnesium chloride, hexahydrate 1.22 g 1.62 g 2.03 g Calcium chloride, dihydrate 0.77 g 1.03 g 1.29 g Glucose anhydrous 172.50 g 230.00 g 287.50 g (equivalent to glucose monohydrate) (189.75 g) (253.00 g) (316.25 g) a: Mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to a ratio essential fatty acids / total fatty acids of 20%. Confidential Document Olimel/Periolimel - FR/H/0419/001-006/MR Page 6 of 32 Proposed common SmPC consolidated March 2013 For OLIMEL N7E: Active substances 1000 ml 1500 ml 2000 ml Refined olive oil+ refined soybean oila 40.00 g 60.00 g 80.00 g Alanine 6.41 g 9.61 g 12.82 g Arginine 4.34 g 6.51 g 8.68 g Aspartic acid 1.28 g 1.92 g 2.56 g Glutamic acid 2.21 g 3.32 g 4.42 g Glycine 3.07 g 4.60 g 6.14 g Histidine 2.64 g 3.97 g 5.29 g Isoleucine 2.21 g 3.32 g 4.42 g Leucine 3.07 g 4.60 g 6.14 g Lysine 3.48 g 5.23 g 6.97 g (equivalent to lysine acetate) (4.88 g) (7.31 g) (9.75 g) Methionine 2.21 g 3.32 g 4.42 g Phenylalanine 3.07 g 4.60 g 6.14 g Proline 2.64 g 3.97 g 5.29 g Serine 1.75 g 2.62 g 3.50 g Threonine 2.21 g 3.32 g 4.42 g Tryptophan 0.74 g 1.10 g 1.47 g Tyrosine 0.11 g 0.17 g 0.22 g Valine 2.83 g 4.25 g 5.66 g Sodium acetate, trihydrate 1.50 g 2.24 g 2.99 g Sodium glycerophosphate, hydrated 3.67 g 5.51 g 7.34 g Potassium chloride 2.24 g 3.35 g 4.47 g Magnesium chloride, hexahydrate 0.81 g 1.22 g 1.62 g Calcium chloride, dihydrate 0.52 g 0.77 g 1.03 g Glucose anhydrous 140.00 g 210.00 g 280.00 g (equivalent to glucose monohydrate) (154.00 g) (231.00 g) (308.00 g) a: Mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to a ratio essential fatty acids / total fatty acids of 20%.
Load more

Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Irish Medicines Board
    Irish Medicines Board IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. No.540 of 2007) PA0167/098/001 Case No: 2063572 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to Baxter Healthcare Limited Caxton Way , Thetford , Norfolk IP24 3SE , United Kingdom an authorisation, subject to the provisions of the said Regulations, in respect of the product CLINIMIX N9G15E, solution for infusion The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 19/05/2009 until 11/12/2009 . Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. ______________________________________________________________________________________________________________________ Date Printed 19/05/2009 CRN 2063572 page number: 1 Irish Medicines Board Part II Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT CLINIMIX ® N9G15E, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLINIMIX ® N9G15E is packaged in a dual compartment plastic bag containing respectively an amino acid solution with electrolytes and a glucose solution with calcium. The injectable amino acid solution contains 15 L -amino acids
    [Show full text]
  • Development of the Medicines Optimisation Assessment Tool (MOAT)
    Department of Practice and Policy UCL School of Pharmacy PhD Thesis – University College London Development of the Medicines Optimisation Assessment Tool (MOAT) Targeting hospital pharmacists' input to reduce risks and improve patient outcomes Cathy Anne Geeson NIHR Clinical Doctoral Research Fellow Pharmacy Department Luton and Dunstable University Hospital 1 Declaration I, Cathy Geeson confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signature: Date: 2 Abstract Abstract Background Medicines optimisation is a key role for hospital pharmacists, but with ever-increasing demands on services, there is a need to increase efficiency while maintaining patient safety. The aim of this study was to use prognostic modelling to develop a prediction tool, the Medicines Optimisation Assessment Tool (MOATTM), to target patients most in need of pharmacists’ input while in hospital. Methods and analysis Patients from adult medical wards at two UK hospitals were prospectively included into this cohort study between April and November 2016. Data on medication related problems (MRPs) were collected by pharmacists at the study sites as part of their routine daily clinical assessment of patients. Data on potential risk factors, such as polypharmacy and use of ‘high-risk’ medicines, were collected retrospectively from the information departments at the study sites, laboratory reporting systems and patient medical records. Multivariable logistic regression was used to determine the relationship between potential risk factors and the study outcome, namely preventable MRPs that were at least moderate in severity. A simplified electronic scoring system (the MOAT) was then developed.
    [Show full text]
  • Pileptic Fosphenytoin
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion Read all of this leaflet carefully before you will be administered this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effect, talk to your doctor or nurse. This includes any side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for 2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is administered 3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used 4. Possible side effects 5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored 6. Contents of the pack and other information 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for TRIOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers. One chamber contains a glucose solution, the second one contains a lipid emulsion and the third one contains an amino acid solution. TRIOMEL is used to provide nutrition to adults and children greater than 2 years of age by a tube into a vein when normal feeding by mouth is not suitable. TRIOMEL must only be used under medical supervision.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Numeta G19E emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION This medicinal product is presented in the form of a three chamber bag. Each bag contains a sterile non-pyrogenic combination of a glucose solution, a paediatric amino acids solution, with electrolytes, and a lipid emulsion, as described below. Container size 50% glucose solution 5.9% amino acids solution 12.5% lipid emulsion with electrolytes 1000 mL 383 mL 392 mL 225 mL If lipid administration is undesirable, the design of the bag allows the possibility to activate only the peel seal between the amino acids/electrolytes and glucose chambers, leaving the peel seal between the amino acids and lipid chambers intact. The content of the bag can subsequently be infused with or without lipids. The composition of the drug product after mixing of the two (amino acids and glucose 2 chamber bag, 775 mL solution) or three (amino acids, glucose and lipid 3 chamber bag, 1000 mL emulsion) chambers are provided in the following table. Page 1 of 28 Composition Active Substance Activated 2CB Activated 3CB (775 mL) (1000 mL) Amino Acid Chamber Alanine 1.83 g 1.83 g Arginine 1.92 g 1.92 g Aspartic acid 1.37 g 1.37 g Cysteine 0.43 g 0.43 g Glutamic acid 2.29 g 2.29 g Glycine 0.91 g 0.91 g Histidine 0.87 g 0.87 g Isoleucine 1.53 g 1.53 g Leucine 2.29 g 2.29 g Lysine monohydrate 2.82 g 2.82 g (equivalent to Lysine) (2.51 g) (2.51 g) Methionine 0.55 g 0.55 g Ornithine hydrochloride 0.73 g 0.73 g (equivalent to Ornithine)
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • European Medicines Agency Referrals Categorised by Type of Referral Procedure and Date Supplementary Tabl
    Supplementary material BMJ Open Supplementary Table 1: European Medicines Agency referrals categorised by type of referral procedure and date Referral category Frequency by CHMP/CMDha opinion date Total 2013 2014 2015 2016 2017 Jan-Jun Article 107i procedures 5 1 0 0 0 6 Article 20 procedures 2 3 1 4 1 11 Article 31 referrals 13 13 5 3 1 35 Total 20 17 6 7 2 52 a) Committee for Medicinal Products for Human Use/Coordination Group for Mutual Recognition and Decentralised Procedures – Human Supplementary Table 2: ATCa therapeutic subgroup of medicinal product by frequency for the 52 included referrals ATC Subgroup definition No. of subgroup referrals code G03 Sex hormones and modulators of the genital system 6 N02 Analgesics 6 A10 Drugs used in diabetes 3 C01 Cardiac therapy 3 M01 Anti-inflammatory and antirheumatic products 3 None Not applicable/available 3 R05 Cough and cold preparations 3 A03 Drugs for functional gastrointestinal disorders 2 B05 Blood substitutes and perfusion solutions 2 C04 Peripheral vasodilators 2 C10 Lipid modifying agents 2 G02 Other gynelogicals 2 L01 Antineoplastic agents 2 M03 Muscle relaxants 2 N05 Psycholeptics 2 R03 Drugs for obstructive airway diseases 2 B01 Antithrombotic agents 1 B02 Antihemorrhagics 1 B03 Antianemic preparations 1 C08 Calcium channel blockers 1 C09 Agents acting on the renin-angiotensin system 1 J01 Antibacterials for systemic use 1 J02 Antimycotics for systemic use 1 J05 Antivirals for systemic use 1 L04 Immunosuppresants 1 M05 Drugs for treatment of bone diseases 1 N03 Antiepileptics 1 N07 Psychoanaleptics 1 R02 Throat preparations 1 R07 Other respiratory system products 1 a) Anatomical Therapeutic Chemical (ATC) Classification System Brown JP, et al.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT CLINIMIX N9G15E, solution for infusion CLINIMIX N9G20E, solution for infusion CLINIMIX N12G20, solution for infusion CLINIMIX N12G20E, solution for infusion CLINIMIX N14G30, solution for infusion CLINIMIX N14G30E, solution for infusion CLINIMIX N17G35, solution for infusion CLINIMIX N17G35E, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CLINIMIX [N9G15E] [N9G20E] [N12G20] [N12G20E] [N14G30] [N14G30E] [N17G35] [N17G35E] is packaged in a dual compartment plastic bag containing respectively an amino acid solution [For Clinimix formulations without electrolytes: without electrolytes] [For Clinimix formulations with electrolytes: with electrolytes] and a glucose solution [For Clinimix formulations without electrolytes: without calcium] [For Clinimix formulations with electrolytes: with calcium]. The injectable amino acid solution contains 15 L-amino acids (8 essential amino acids) needed for the protein synthesis. The amino acid profile is the following: - Essential amino acids/Total amino acids = 41.3 % - Essential amino acids/Total nitrogen = 2.83 - Branched chain amino acids/Total amino acids = 19 % The quantitative composition of CLINIMIX [N9G15E] [N9G20E] [N12G20] [N12G20E] [N14G30] [N14G30E] [N17G35] [N17G35E] is the following: [For Clinimix N9G15E] 5.5% Amino acid solution with 15% Glucose solution with calcium electrolytes Active ingredients L-Leucine 4.02 g/l L-Phenylalanine 3.08 g/l L-Methionine 2.20 g/l L-Lysine 3.19 g/l (as L-Lysine hydrochloride)
    [Show full text]
  • Estonian Statistics on Medicines 2014
    Estonian Statistics on Medicines 2014 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 153,9425 A01 STOMATOLOGICAL PREPARATIONS 0,0769 A01A STOMATOLOGICAL PREPARATIONS 0,0769 A01AB Antiinfectives and antiseptics for local oral treatment 0,0769 A01AB09 Miconazole(O) 7361,6 g 0,2 g 0,0769 A01AB12 Hexetidine(O) 2482960 ml A01AB81 Neomycin + Benzocaine(C) 24400 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone + Thymol(dental) 3081 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine + Cetylpyridinium chloride(gingival) 189390 g A01AD81 Lidocaine + Cetrimide(O) 24760 g A01AD82 Choline salicylate(O) 878880 pieces A01AD83 Lidocaine + Chamomille extract(O) 331510 g A01AD86 Lidocaine + Eugenol(gingival) 600 g A01AD90 Lidocaine + Paraformaldehyde(dental) 45 g A02 DRUGS FOR ACID RELATED DISORDERS 39,9050 A02A ANTACIDS 1,0057 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1,0057 A02AD81 Aluminium hydroxide + Magnesium hydroxide(O) 615400 pieces 10 pieces 0,1285 A02AD81 Aluminium hydroxide + Magnesium hydroxide(O) 2824956 ml 50 ml 0,1180 A02AD82 Aluminium aminoacetate + Magnesium oxide(O) 398580 pieces 10 pieces 0,0832 A02AD83 Calcium carbonate + Magnesium carbonate(O) 3237240 pieces 10 pieces 0,6760 A02AF Antacids with antiflatulents A02AF80 Aluminium hydroxide + Magnesium hydroxide + Simeticone(O) 96560 ml DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE A02B 38,8993 (GORD) A02BA H2-receptor antagonists
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • Kongressjournal Wmw Wiener Medizinische Wochenschrift
    Band 9 / Heft 3 www.springer.at/wmw-skriptum ISSN Print 1613-3803 P. b. b. Verlagspostamt 1201 Wien / Plus.Zeitung 07Z037513P 03/12 SpringerMedizin.at Springer Medizin /schwerpunkt/oegho-2012 .at skriptum/schwerpunkt/oegho-2012 Kongressjournal wmw Wiener Medizinische Wochenschrift 12. bis 14. April 2012, Congress Graz Frühjahrstagung 2012 Aktuelle Vorträge in der der Österreichischen Gesellschaft ÄrzteWoche-APP für Hämatologie und Onkologie Ärzte Nr. 35, Donnerstag, 1. September 2011, 25. Jahrgang 247,10,0 Eurouo günstigegüg st ger* Ärzte90 Woche Zur Behandlung von fortgeschrittenem Mammakarzinom bei postmenopausalen Frauen. über 56 % günstiger** 247,10,0 Eurouo güggünstiger st ge * 30 und der Arbeitsgemeinschaft hämato-onkologischer 90 Zur abBehandlung 1. 8. in dervon greenfortgeschritt box Mammakarzinom bei postmenop PANTONE Blue 287C enem PANTONE Red 192C Grüße aus Genericon ausalen Frauen. * Arimidex 1 mg 3x30 Stk. vgl. mit Anastrozol Genericon 1 mg 1x90 Stk., KKP 08/11 ** Arimidex 1 mg 30 Stk. vgl. mit Anastrozol Genericon 1 mgüber 30 Stk., K56KP 08/11 % günstiger** 30 Diät-Limos ab 1. 8. in der green box Grüße aus Genericon PANTONE Blue 287C * Arimidex 1 mg 3x30 Stk. vgl. mit Anastroz ** Arimidex PANTONE Red 192C 1 mg 30 Stk. vgl. mit Anastrozolol Generico Genericon 1 mg 1x90 Stk., KKP 08/11 n 1 mg 30 Stk., KK P 08/11 9 4 Stück 0 2/ A 0x90 0 P / einmal wöchentlich Filmtabletten 2 mg _ 35 5 4 Risedronat STADA 0x 4 Jede Filmtablette enthält 35 mg Risedronat-Natrium, entsprechend 32,5 mg RIS3 Pfl egepersonen in Österreich (AHOP) Universalgelehrter Risedronsäure. Enthält Lactose. Packungsbeilage beachten.
    [Show full text]